Gastroduodenal gastrointestinal stromal tumour: a case series and review of literature


  • Kishore Abuji Department of Surgery, PGIMER, Chandigarh, India
  • Divya Dahiya Department of Surgery, PGIMER, Chandigarh, India
  • Ashwin Banda Department of Surgery, PGIMER, Chandigarh, India
  • Surinder S. Rana Department of Gastroenterology, PGIMER, Chandigarh, India
  • Arunanshu Behera Department of Surgery, PGIMER, Chandigarh, India



Gastroduodenal tumour, GIST, Gastric GIST, Duodenal GIST


Gastrointestinal stromal tumour (GIST) is the most common non-epithelial mesenchymal tumour and comprises 0.1-3% of all gastrointestinal (GI) tract tumours. They express tyrosine kinase and are potentially malignant. Therefore, early diagnosis and surgical resection is the key for good outcome. This is a retrospective analysis of medical records of five patients of gastroduodenal GIST who were managed in the department of surgery between 2014 and 2015. Demographic profile, clinical presentation, laboratory parameters, diagnostic imaging, treatment details, histopathology and long-term outcome was analysed. Patients were followed up regularly in surgery outpatient clinic. Last follow up was in December 2022. All were female; three of them presented with melena and two with lump abdomen. Patients with gastric GIST underwent sleeve resection in two and antrectomy in one patient. Patient with duodenal GIST underwent excision of tumour with primary repair of duodenum. Fifth patient had metastatic duodenal GIST; Imatinib was started in view of irresectable disease at presentation. However, there was tumour progression and she succumbed to illness seven months after treatment initiation with Imatinib. Histopathology revealed low grade GIST in two, intermediate grade in one and malignant in one.  Patient with malignant GIST received Imatinib for 2 years. All four patients are well on follow up with no sign of local and distant recurrence.


Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;152:1259-69.

Singhal T, Doddi S, Leake T, Parsi S, Hussain A, Chandra A et al. Upper gastrointestinal bleeding due to gastric stromal tumour: a case report. Cases J. 2010;3:58.

Miettinen M, Lasota J. Gastrointestinal stromal tumors: definition, clinical, histological, immunohistochemical, and moleculargenetic features and differential diagnosis. Virchows Arch. 2001;438(1):1-12.

Levy AD, Remotti HE, Thompson WM, Sobin LH, Miettinen M. Gastrointestinal stromal tumors: radiologic features with pathologic correlation. Radiographics. 2003;23(2):283-304.

Mantese G. Gastrointestinal stromal tumor: epidemiology, diagnosis, and treatment. Curr Opin Gastroenterol. 2019;35:555-9.

Joensuu H. Gastrointestinal stromal tumor (GIST). Ann Oncol. 2006;17:280-6.

DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231(1):51-8.

Marano L, Torelli F, Schettino M, Porfidia R, Reda G, Grassia M et al. Combined laparoscopic-endoscopic Brendezvous^ procedure for minimally invasive resection of gastrointestinal stromal tumor of the stomach. Am Surg. 2011;77(8):1100-2.

Wilhelm D, Von Delius S, Burian M, Schneider A, Frimberger E, Meining A et al. Simultaneous use of laparoscopy and endoscopy for minimally invasive resection of gastric subepithelia masses-analysis of 93 interventions. World J Surg. 2008;32(6):1021-8.

Davila JS, Mombian D, Gines A, Sanchez-Montes C, Araujo I, Saavendra-Perez D et al. Endoscopic-assisted laparoscopic resection for gastric sub epithelial tumors. Surg Endosc. 2016;30(1):199-203.

Tan CB, Zhi W, Shahzad G, Mustacchia P. Gastrointestinal stromal tumors: a review of case reports, diagnosis, treatment, and future directions. Gastroenterology. 2012;2012:595968.

Akahoshi K, Oya M, Koga T, Shiratsuchi Y. Current clinical management of gastrointestinal stromal tumor. World J Gastroenterol. 2018;24(26):2806-17.

Joensuu H, Martin-Broto J, Nishida T, Reichardt P, Schöffski P, Maki RG. Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery. Eur J Cancer 2015;51:1611-7.






Case Series